Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer

Kumar

Magnetic Resonance Imaging

et al. 2017

mentioning

confidence: 99%

Prebiopsy multiparametric MRI‐based risk score for predicting prostate cancer in biopsy‐naive men with prostate‐specific antigen between 4–10 ng/mL

Kumar

Magnetic Resonance Imaging

et al. 2017

“…MRI may add value as both a pre-biopsy risk assessment tool that may influence the decision whether to perform biopsy as well as a minimally invasive method for tumor localization to direct targeted biopsy (2). Incorporating MRI with MRI-US-fusion targeted biopsy has shown improved sensitivity for detecting high grade prostate cancer while reducing the detection of clinically insignificant disease (3,4). In this review, we present our contemporary experience with prostate MRI and MRI-US-fusion targeted biopsy, highlighting our institutional program development and outcomes.…”

Section: Introductionmentioning

confidence: 99%

MRI-fusion biopsy: the contemporary experience

Bjurlin

Rosenkrantz

Taneja

2017

Transl. Androl. Urol.

Advancements in magnetic resonance imaging (MRI) and MRI-ultrasound (US)-fusion targeted biopsy have resulted in a paradigm shift in the diagnosis of prostate cancer by overcoming the limitations of systematic biopsy. Prebiopsy MRI and MRI-US-fusion biopsy results in an increased detection of clinically significant disease, reduction in the detection of indolent disease, and allows for tumor localization during targeted biopsy. With these advantages, we have adopted a prebiopsy MRI and MRI-US-fusion biopsy diagnostic care pathway for all men at risk for prostate cancer and have performed more than 1900 biopsies to date. Herein we present our institutional development of MRI-US-fusion biopsy and highlight our results in those men who have had a previous negative biopsy, no prior biopsy, and those with a prior cancer diagnosis who may be candidate for active surveillance. Risk stratification with biomarkers and nomograms may allow for further counseling on the need for biopsy and the risk of harboring clinically significant disease.

Investig Magn Reson Imaging

“…Although many studies revealed the usefulness of mpMRI before transrectal ultrasound (TRUS)-guided biopsy (10)(11)(12)(13), prostate MRI is still commonly performed after diagnosis of prostate cancer by TRUS-guided biopsy. As post-biopsy hemorrhage has been thought to decrease detection and staging accuracy of MRI in prostate cancer, prostate MRI is recommended to be performed more than eight weeks after the biopsy to provide time This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.…”

Section: Introductionmentioning

confidence: 99%

Multiparametric MRI of Prostate Cancer after Biopsy: Little Impact of Hemorrhage on Tumor Staging

Choi

Jung

Park

et al. 2017

Original ArticlePurpose: To evaluate differences in staging accuracy of prostate cancer according to the extent of hemorrhage on multiparametric MRI performed after biopsy. Materials and Methods:We enrolled 71 consecutive patients with biopsy-proven prostate cancer. Patients underwent MRI followed by a prostatectomy at our institution in 2014. Two radiologists reviewed the MRI to determine the tumor stage. Correlation between biopsy-MRI interval and extent of hemorrhage was evaluated. Regression analyses were used to determine factors associated with accuracy of tumor staging. Results: The mean interval between biopsy and MRI was 17.4 ± 10.2 days (range, 0-73 days). The interval between prostate biopsy and MRI and the extent of hemorrhage were not significantly correlated (P = 0.880). There was no significant difference in the accuracy rate of staging between the small and large hemorrhage groups. Conclusion: Biopsy-induced hemorrhage in the prostate gland is not sufficiently absorbed over time. The extent of hemorrhage and the short interval between biopsy and MRI may not impair tumor detection or staging on multiparametric MRI.